Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 7 | 2025 | 134 | 1.760 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 99 | 1.700 |
Why?
|
| Brain Neoplasms | 6 | 2026 | 1297 | 0.990 |
Why?
|
| Organs at Risk | 1 | 2025 | 40 | 0.920 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 100 | 0.870 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 209 | 0.760 |
Why?
|
| Brachytherapy | 2 | 2019 | 80 | 0.660 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2019 | 16 | 0.590 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 1541 | 0.580 |
Why?
|
| Radiotherapy Dosage | 3 | 2025 | 214 | 0.570 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2026 | 613 | 0.350 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1417 | 0.330 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2020 | 32 | 0.320 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2020 | 33 | 0.310 |
Why?
|
| Mastectomy | 2 | 2020 | 75 | 0.310 |
Why?
|
| Arteriovenous Fistula | 2 | 2020 | 55 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 327 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2020 | 155 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 1276 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 758 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2026 | 3911 | 0.210 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2026 | 239 | 0.210 |
Why?
|
| Regression Analysis | 1 | 2025 | 773 | 0.200 |
Why?
|
| Retrospective Studies | 13 | 2025 | 17648 | 0.200 |
Why?
|
| Hippocampus | 2 | 2024 | 805 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12936 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2024 | 685 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 329 | 0.170 |
Why?
|
| Radiation Oncology | 1 | 2020 | 28 | 0.160 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 73 | 0.160 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 39 | 0.150 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 48 | 0.150 |
Why?
|
| Kallikreins | 1 | 2019 | 26 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2116 | 0.150 |
Why?
|
| Pneumonectomy | 1 | 2020 | 151 | 0.150 |
Why?
|
| Mesothelioma | 1 | 2020 | 91 | 0.150 |
Why?
|
| Humans | 21 | 2026 | 131504 | 0.140 |
Why?
|
| Teratoma | 1 | 2019 | 124 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 275 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 236 | 0.140 |
Why?
|
| Corticotrophs | 1 | 2017 | 1 | 0.140 |
Why?
|
| Organ Size | 1 | 2019 | 434 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 353 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2024 | 6485 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 2646 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 1322 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 204 | 0.130 |
Why?
|
| Risk | 1 | 2019 | 739 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 909 | 0.130 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 78 | 0.130 |
Why?
|
| Prostate | 1 | 2019 | 415 | 0.120 |
Why?
|
| Adenoma | 1 | 2017 | 145 | 0.120 |
Why?
|
| Aged | 7 | 2024 | 21238 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2014 | 110 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5277 | 0.100 |
Why?
|
| Middle Aged | 7 | 2024 | 28839 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1258 | 0.080 |
Why?
|
| Male | 9 | 2024 | 65158 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 393 | 0.070 |
Why?
|
| Time Factors | 1 | 2019 | 6273 | 0.070 |
Why?
|
| Female | 11 | 2026 | 71087 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 31666 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 1078 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 5120 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 2149 | 0.050 |
Why?
|
| Adolescent | 5 | 2020 | 20917 | 0.050 |
Why?
|
| Steroids | 1 | 2024 | 172 | 0.050 |
Why?
|
| Lung | 2 | 2021 | 1565 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 265 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2024 | 356 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2021 | 11 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2022 | 120 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 3344 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2026 | 2143 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 208 | 0.040 |
Why?
|
| Michigan | 1 | 2019 | 47 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2020 | 178 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4951 | 0.040 |
Why?
|
| Algorithms | 1 | 2026 | 1685 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2019 | 145 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2019 | 153 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 2017 | 19 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2019 | 376 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2019 | 397 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1405 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3113 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 375 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1522 | 0.030 |
Why?
|
| Child | 3 | 2020 | 26239 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 10092 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1404 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2985 | 0.020 |
Why?
|
| Vagina | 1 | 2014 | 211 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1356 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2205 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8589 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6916 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 13300 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 15047 | 0.010 |
Why?
|